Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 64
- Registration Number
- NCT05728619
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
🇨🇳Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 18
- Registration Number
- NCT05698524
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT05691491
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- TVAX Biomedical
- Target Recruit Count
- 120
- Registration Number
- NCT05685004
- Locations
- 🇺🇸
Center for Neurosciences, Tucson, Arizona, United States
🇺🇸Providence St. Vincent, Portland, Oregon, United States
🇺🇸Cedar-Sanai Medical Center, Los Angeles, California, United States
Glutamate Inhibitors in Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 120
- Registration Number
- NCT05664464
- Locations
- 🇨🇭
University Hospital Zurich, Zürich, Zurich, Switzerland
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05663125
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT05634707
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 234
- Registration Number
- NCT05629702
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
🇬🇧Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 78
- Registration Number
- NCT05600491
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- The Second Hospital of Hebei Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT05589961
- Locations
- 🇨🇳
the Second Hospital of HeBei Medical University, Shijia Zhuang, Hebei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.